Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: A Phase 3 Randomized Clinical Trial - PubMed
3 hours ago
- #Gastric Cancer
- #Peritoneal Metastasis
- #Intraperitoneal Chemotherapy
- Adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 significantly improved overall survival in gastric cancer with peritoneal metastasis.
- Median overall survival was 19.4 months in the intraperitoneal group versus 13.9 months in the intravenous-only group, with a hazard ratio of 0.67.
- Median progression-free survival was also better in the intraperitoneal group (11.2 vs. 7.2 months, hazard ratio 0.72).
- Grade 3 or 4 adverse events were similar between groups (38.5% vs. 41.9%), with no treatment-related deaths.
- This phase 3 trial suggests intraperitoneal therapy is a promising first-line option for gastric cancer with peritoneal metastasis.